Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Basiliximab for aGVHD Prophylaxis in UCBT
NCT06480630Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of USTC
- Start
- Jul 2024
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of basiliximab in Acute Graft-Versus-Host Disease (aGvHD), sponsored by The First Affiliated Hospital of USTC. Primary endpoint: Cumulative incidence of grade III-IV acute graft-versus-host disease at 100 days. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
basiliximab
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT06480630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06480630.